Brian T. Hickner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brian T. Hickner has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Sanjeev A. Vasudevan
Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Texas Children's Hospital Surgical Oncology Program and Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
2 shared publications- Alexander Bondoc
Division of Pediatric General and Thoracic Surgery, Department of Surgery, Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine Cincinnati Ohio USA
1 shared publication Andres F. Espinoza
Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Texas Children's Hospital Surgical Oncology Program and Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
1 shared publication- Andrew A. Badachhape
Department of Radiology, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, 77030, USA
1 shared publication - Bruce J. Aronow
Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
1 shared publication - Celia D. Flores
Department of Surgery, Division of Pediatric Surgery, Texas Children's Hospital, 6701 Fannin St. Houston, TX 77030
1 shared publication
Latest Publications
- 6 May 2026
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (8) , 163195
Oncologic outcomes of parenchyma-sparing resection for hepatoblastoma
- 6 May 2026
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (8) , 163195
Oncologic outcomes of parenchyma-sparing resection for hepatoblastoma
- 12 August 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (1) , 162543
Risk of missed diagnoses when choosing non-operative management of pediatric uncomplicated appendicitis
- 12 August 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (1) , 162543
Risk of missed diagnoses when choosing non-operative management of pediatric uncomplicated appendicitis
- Open Access
Oncogenic Role of Aberrant EZH2 in Hepatoblastoma
Hepatoblastoma (HB) is the most common pediatric liver malignancy. However, its cellular origin and molecular drivers remain poorly defined. Using single-nuclear RNA sequencing (snRNA-seq), we identified a proliferative, hepatocyte-derived tumor cell population (cycling Hep T ) enriched for Enhancer of Zeste Homolog 2 ( EZH2) expression, particularly in the aggressive embryonal subtype. Integrative genomic and transcriptomic profiling confirmed EZH2 overexpression. Disruption of the PRC2 complex was evident through mislocalization and reduced expression of SUZ12, a core component. EZH2 overexpression correlated with upregulation of mitotic regulators such as AURKB and Ki67 in human HB gene expression analysis as compared to background liver. Targeted sequencing identified variants of uncertain significance in EZH2 and SUZ12 in 11 of 11 patient tumors. Pharmacologic inhibition of EZH2 with EPZ-6438 reduced proliferation and sensitized HB cells to cisplatin through gene regulation, potentially modulating platinum accumulation both in vitro and in vivo . In summary, EZH2 promotes HB progression through epigenetic silencing and noncanonical signaling pathways. These findings support EZH2’s contribution to HB pathogenesis, therefore identifying it as a novel therapeutic target. STATEMENT OF SIGNIFICANCE: EZH2 is enriched in hepatoblastoma, suggesting its role in early tumorigenesis. Its inhibition, combined with cisplatin, produces synergistic anti-tumor effects, supporting EZH2 as both an oncogenic and therapeutic target.
Open AccessOncogenic Role of Aberrant EZH2 in Hepatoblastoma
Hepatoblastoma (HB) is the most common pediatric liver malignancy. However, its cellular origin and molecular drivers remain poorly defined. Using single-nuclear RNA sequencing (snRNA-seq), we identified a proliferative, hepatocyte-derived tumor cell population (cycling Hep T ) enriched for Enhancer of Zeste Homolog 2 ( EZH2) expression, particularly in the aggressive embryonal subtype. Integrative genomic and transcriptomic profiling confirmed EZH2 overexpression. Disruption of the PRC2 complex was evident through mislocalization and reduced expression of SUZ12, a core component. EZH2 overexpression correlated with upregulation of mitotic regulators such as AURKB and Ki67 in human HB gene expression analysis as compared to background liver. Targeted sequencing identified variants of uncertain significance in EZH2 and SUZ12 in 11 of 11 patient tumors. Pharmacologic inhibition of EZH2 with EPZ-6438 reduced proliferation and sensitized HB cells to cisplatin through gene regulation, potentially modulating platinum accumulation both in vitro and in vivo . In summary, EZH2 promotes HB progression through epigenetic silencing and noncanonical signaling pathways. These findings support EZH2’s contribution to HB pathogenesis, therefore identifying it as a novel therapeutic target. STATEMENT OF SIGNIFICANCE: EZH2 is enriched in hepatoblastoma, suggesting its role in early tumorigenesis. Its inhibition, combined with cisplatin, produces synergistic anti-tumor effects, supporting EZH2 as both an oncogenic and therapeutic target.